{
    "id": 31980,
    "fullName": "BRCA2 S1989fs",
    "impact": "frameshift",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "BRCA2 S1989fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 1989 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the effects of other truncation mutations downstream of S1989 (PMID: 10570174, PMID: 18607349), S1989fs is predicted to lead to a loss of Brca2 protein function; however, the corresponding cDNA change has been predicted to act as a reversion mutation in the context of a specific inactivating BRCA2 mutation, potentially leading to restoration of the BRCA2 open reading frame and wild-type protein function, as demonstrated by association with acquired resistance to a PARP inhibitor (PMID: 31501807).",
            "references": [
                {
                    "id": 16759,
                    "pubMedId": 31501807,
                    "title": "Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31501807"
                },
                {
                    "id": 3274,
                    "pubMedId": 10570174,
                    "title": "Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/10570174"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 6349,
                    "pubMedId": 18607349,
                    "title": "Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18607349"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 675,
        "geneSymbol": "BRCA2",
        "terms": [
            "BRCA2",
            "BRCC2",
            "BROVCA2",
            "FACD",
            "FAD",
            "FAD1",
            "FANCD",
            "FANCD1",
            "GLM3",
            "PNCA2",
            "XRCC11"
        ]
    },
    "variant": "S1989fs",
    "createDate": "01/07/2020",
    "updateDate": "01/07/2020",
    "referenceTranscriptCoordinates": {
        "id": 186306,
        "transcript": "NM_000059",
        "gDna": "chr13:g.(32340319_32340320)",
        "cDna": "c.(5965_5964)",
        "protein": "p.S1989fs",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19699,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with prostate cancer harboring a germline mutation, BRCA2 S1982fs, and a secondary somatic mutation, BRCA2 H1918fs, progressed while being treated with Lynparza (olaparib), and was found via ctDNA testing to have acquired 11 BRCA2 mutations that were predicted to restore the BRCA2 open reading frame, BRCA2 S1982_A1996del, S1985fs, S1989fs, Q1987fs, Q1998fs, A1981_V1986delinsI, F2000fs, S1982_K1984del, E1912fs, and S917_H1918del (PMID: 31501807).",
            "molecularProfile": {
                "id": 34436,
                "profileName": "BRCA2 S917_H1918del BRCA2 E1912fs BRCA2 H1918fs BRCA2 A1981_V1986delinsI BRCA2 S1982_A1996del BRCA2 S1982_K1984del BRCA2 S1982fs BRCA2 S1985fs BRCA2 Q1987fs BRCA2 S1989fs BRCA2 Q1998fs BRCA2 F2000fs"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16759,
                    "pubMedId": 31501807,
                    "title": "Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31501807"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34435,
            "profileName": "BRCA2 S1989fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34436,
            "profileName": "BRCA2 S917_H1918del BRCA2 E1912fs BRCA2 H1918fs BRCA2 A1981_V1986delinsI BRCA2 S1982_A1996del BRCA2 S1982_K1984del BRCA2 S1982fs BRCA2 S1985fs BRCA2 Q1987fs BRCA2 S1989fs BRCA2 Q1998fs BRCA2 F2000fs",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 186306,
            "transcript": "NM_000059",
            "gDna": "chr13:g.(32340319_32340320)",
            "cDna": "c.(5965_5964)",
            "protein": "p.S1989fs",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}